Author

Guy Newsome

Observed names: G. Newsome, Guy A. Newsome

Institutions: Center for Molecular Medicine and Immunology, Vanderbilt University Medical Center

Observed institutions: Johns Hopkins University, Johns Hopkins Medicine, NYU Langone Health, Universitätsmedizin Göttingen, Immunomedics (United States), Center for Molecular Medicine and Immunology, New York University, University of Göttingen, Columbia University, Vanderbilt University Medical Center

OpenAlex ID: A5032159174

Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer

2004 · David E. Modrak, Thomas M. Cardillo, et al. · Cancer Research · 68

Improved iodine radiolabels for monoclonal antibody therapy.

2003 · Rhona Stein, Serengulam V Govindan, et al. · PubMed · 66

PAM4 enzyme immunoassay alone and in combination with CA 19‐9 for the detection of pancreatic adenocarcinoma

2012 · David V. Gold, Jochen Gaedcke, et al. · Cancer · 47

Detection of Early-Stage Pancreatic Adenocarcinoma

2010 · David V. Gold, Michael Goggins, et al. · Cancer Epidemiology Biomarkers & Prevention · 45

Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

2013 · David V Gold, Guy Newsome, et al. · Molecular Cancer · 30

Differentiation of Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis by PAM4 Immunohistochemistry

2014 · Chanjuan Shi, Nipun Merchant, et al. · Archives of Pathology & Laboratory Medicine · 24

Detection of early-stage pancreatic carcinoma

2009 · D. Gold, D. E. Modrak, et al. · Journal of Clinical Oncology · 18

Evaluation of a novel MUC1 biomarker/target antigen for pancreatic cancer

2006 · D. V. Gold, D. E. Modrak, et al. · Journal of Clinical Oncology · 3

Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay.

2012 · David V. Gold, Jochen Gaedcke, et al. · Journal of Clinical Oncology · 2

Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma.

2012 · David V. Gold, Jochen Gaedcke, et al. · Journal of Clinical Oncology · 1

Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16)

2005 · David Modrak, Habibe Karacay, et al. · International Journal of Oncology · 1

Abstract 1141: MAb-PAM4 can differentiate between pancreatic ductal adenocarcinoma and chronic pancreatitis.

2013 · David V. Gold, Chanjuan Shi, et al. · Cancer Research

Abstract 4622: PAM4-antigen levels in the serum of patients with pancreatic carcinoma: Early detection of disease and correlation with responses to radioimmunotherapy

2010 · David V. Gold, Guy Newsome, et al. · Cancer Research

Evaluation of a MAb-PAM4-defined MUC1 immunoassay as a potentially new diagnostic test for pancreatic cancer

2005 · D. V. Gold, G. Newsome, et al. · Journal of Clinical Oncology

A pretargeted bispecific PAM4-based antibody system for nuclear imaging and therapy of pancreatic cancer

2005 · Habibe Karacay, Guy Newsome, et al. · Cancer Research

Works count: 15

Citation count: 305

H-index: 7

I10-index: 7